SOPHiA GENETICS Q3 2026 Revenue Rises 25% to $24.3 Million as Net Loss Narrows Slightly

SOPHiA GENETICS reported third-quarter 2026 revenue of $24.3 million, up 25% year-over-year, and said it expects full-year revenue at the upper end of its $94 million to $96 million guidance. The company announced the results on November 3, 2026, according to PR Newswire.

SOPHiA GENETICS' Quarterly Results and Customer Growth

SOPHiA GENETICS is an AI-native healthcare technology company that runs the SOPHiA DDM platform, which analyzes genomic and multimodal data for hospitals, laboratories and biopharma institutions. The company reported a net loss of $20.3 million for the quarter, up 1% year-over-year, and an adjusted EBITDA loss of $6.1 million, improving 31% year-over-year. Gross margin was 65.7% on a reported basis and 72.8% on an adjusted basis, compared with 66.3% reported and 73.1% adjusted in the prior year period.

"Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew 25% year-over-year," said Ross Muken, Chief Executive Officer of SOPHiA GENETICS. "We also meaningfully improved adjusted EBITDA by 31%, bringing us closer to profitability and further demonstrating the highly scalable nature of our AI-native platform and business model."

The company performed a record 118,000 analyses on SOPHiA DDM in the quarter, representing 19% year-over-year volume growth. It signed 30 new core genomic customers in the third quarter, which are expected to begin generating revenue over the next twelve months, and reached 551 core genomics customers as of September 30, 2026, up from 488 a year earlier. Net Dollar Retention increased to 118% in the third quarter of 2026, up from 108% in the third quarter of 2025.

SOPHiA GENETICS' BioPharma Deals and Platform Scale

According to akta.pro company records, SOPHiA GENETICS' platform is used by more than 990 healthcare institutions across more than 75 countries, and more than 2.5 million genomic profiles have been analyzed on SOPHiA DDM since 2014. The same records list a June 2026 post-IPO equity round of $57.5 million and total funding of $322.7 million.

In the third quarter, SOPHiA GENETICS signed a multi-year agreement with AstraZeneca to launch two companion diagnostic programs: a decentralized Solid Tumor CDx and a Hematological Oncology test for patients with blood cancer. It also signed a new multimodal AI collaboration with a top BioPharma company to develop a predictor for identifying bladder cancer patients most likely to benefit from a targeted therapy.

SOPHiA GENETICS' Path to the Third Quarter

In October 2026, Myriad Genetics and SOPHiA announced a collaboration with AstraZeneca to advance PrGIS, a prostate cancer biomarker for genomic instability, with the companies aiming to develop companion diagnostics and present research at ESMO 2026, Investing.com reported. In June 2026, SOPHiA GENETICS signed a memorandum of understanding with Memorial Sloan Kettering Cancer Center to form a joint venture establishing a precision oncology hub in New York, combining MSK's 150,000+ sequenced tumor samples and clinical data with the SOPHiA DDM AI platform, according to akta.pro company records. In May 2026, the company partnered with UK pathology provider Synnovis to deliver MSK-ACCESS liquid biopsy testing powered with SOPHiA DDM to lung and breast cancer patients across the U.K. as part of NHS England's 'blood test-first' program, the same records show.

SOPHiA GENETICS' 2027 Profitability Target

SOPHiA GENETICS reaffirmed its commitment to crossing over to positive adjusted EBITDA in the second half of 2027. The company guided to an adjusted EBITDA loss between $29 million and $32 million for full-year 2026, compared with $41.5 million in fiscal 2025.